New Ferrocene Formates Bearing Isoxazole Moieties: Synthesis, Characterization,
X-ray Crystallography, and Preliminarily Cytotoxicity against A549, HCT116, and
MCF-7 Cell Lines

Jianping      Yong; Canzhong      Lu; Minxue      Yang; Xiaoyuan      Wu

doi:10.2174/1381612828666220822113738

Abstract

Aims: To develop new anticancer agents based on ferrocene core.

Background: Cancer has become the major cause of human death globally. The death caused by cancer mainly focuses on lung cancer, breast cancer, liver cancer, carcinoma of the colon, and rectum. Some small molecular inhibitors have been authorized by FDA for the treatment of cancer and several candidates are in different phases of clinical trials. However, cancer chemotherapy is still highly inadequate. Thus, it is indispensable to develop novel anticancer agents.

Objective: Based on the previous good results, twelve novel structures of ferrocene formates bearing isoxazole moiety (3a-3l) were synthesized in this work for the development of anticancer agents.

Methods: The target compounds were synthesized using Ferrocenecarboxylic acid and 3-[(R)-substitutedphenyl]- isoxazole-5-methanol catalyzed by DCC and DMAP. The structures of target compounds were characterized by ¹H NMR, ¹³C NMR, MS, HR-MS and XRD. Then, their preliminarily in vitro cytotoxicity against A549, HCT116, and MCF-7 cell lines was evaluated using the MTT method.

Results: The results showed that most compounds exhibited moderate cytotoxicity against A549, HCT116, and MCF-7 cell lines compared with the positive control gefitinib. However, (3b, 3c, 3e, 3j, and 3k) simultaneously exhibited stronger inhibitory activity against A549, HCT116, and MCF-7 cell lines, which can be regarded as promising metal-based lead compounds for the development of anticancer agents.

Conclusion: In this work, twelve new structures of ferrocene derivatives containing isozaole moiety were synthesized and their cytotoxicity against 549, HCT116, and MCF-7 cell lines was evaluated. (3b, 3c, 3e, 3j, and 3k) simultaneously exhibited stronger inhibitory activity towards A549, HCT116, and MCF-7 cell lines, which can be regarded as promising metal-based lead compounds for the development of anticancer agents.

Keywords: Ferrocene formates, isoxazole moiety, synthesis, structural characterization, XRD, HR-MS, anticancer activity.

« Previous Next »

[1]
Cancer facts and figure. 2017. Available from: https://www.cancer.org/research/cancer-facts-statistics/allcancer-facts-figures/cancer-facts-figures-2017.html

[2]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin  2016; 66(2): 115-32.
 [http://dx.doi.org/10.3322/caac.21338] [PMID:  26808342]

[3]
(a) Grosios K, Traxier P. Tryosine kinase targets in drug discovery. Drugs Future  2003; 28(7): 679-97.
 [http://dx.doi.org/10.1358/dof.2003.028.07.857184]; 
(b) Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mouse-trap? A review of the clinical evidence. Crit Rev Oncol Hematol  2012; 83(3): 407-21.
 [http://dx.doi.org/10.1016/j.critrevonc.2011.11.010] [PMID:  22257651]

[4]
van Staveren DR, Metzler-Nolte N. Bioorganometallic chemistry of ferrocene. Chem Rev  2004; 104(12): 5931-85.
 [http://dx.doi.org/10.1021/cr0101510] [PMID:  15584693]

[5]
Braga SS, Silva AMS. A new age for iron: Antitumoral ferrocenes. Organometallics  2013; 32(20): 5626-39.
 [http://dx.doi.org/10.1021/om400446y]

[6]
Yong JP, Lu CZ, Wu XY. Synthesis of isoxazole moiety containing ferrocene derivatives and preliminarily in vitro anticancer activity. MedChemComm  2014; 7(7): 968-72.
 [http://dx.doi.org/10.1039/c4md00151f]

[7]
Liu LJ, Yong JP, Dai XJ, Jia J, Wang XZ, Wang JW. Synthesis of novel isoxazole contained glycyrrhetinic acid derivatives. Chem J Chin Univ  2006; 27(9): 1669-72.

[8]
Yong JP, Lu CZ, Wu X. Potential anticancer agents. I. Synthesis of isoxazole moiety containing quinazoline derivatives and preliminarily in vitro anticancer activity. Anticancer Agents Med Chem  2015; 15(1): 131-6.
 [http://dx.doi.org/10.2174/1871520614666140812105445] [PMID:  25142319]

[9]
(a) Yong JP, Aisa HA. Chemical modification of rupestonic acid and preliminarily in vitro antiviral activity against influenza A3 and B viruses. Bull Korean Chem Soc  2011; 32(4): 1293-7.
 [http://dx.doi.org/10.5012/bkcs.2011.32.4.1293]; 
(b) Yong JP, Aisa HA. Synthesis of rupestonic acid amide derivatives and their in vitro activity against type A3 and B flu virus and herpes simplex I and II. Chem Nat Compd  2008; 44(3): 311-4.
 [http://dx.doi.org/10.1007/s10600-008-9050-y]

[10]
Lapić J, Djaković S, Kodrin I, Mihalić Z, Cetina M, Rapić V. Preparation and conformation analysis of N-(ferrocenoyl)dipeptide esters and their 1′-acetyl derivatives. Eur J Org Chem  2010; 2010(13): 2512-24.
 [http://dx.doi.org/10.1002/ejoc.200901435]

[11]
Dallagi T, Saidi M, Vessières A, Huché M, Jaouen G, Top S. Synthesis and antiproliferative evaluation of ferrocenyl and cymantrenyl triaryl butene on breast cancer cells. Biodistribution study of the corresponding technetium-99m tamoxifen conjugate. J Organomet Chem  2013; 734: 69-77.
 [http://dx.doi.org/10.1016/j.jorganchem.2012.11.035]

[12]
Sheldrick GM. SHELXS-97, Program for Solution of Crystal Structures. Phd Thesis University of Göttingen, Germany 1997.

[13]
Sheldrick GM. SHELXS-97, program for refinement of crystal structures. Phd Thesis University of Göttingen, Germany 1997.

Rights & Permissions Print Cite

Article Metrics

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1381612828666220822113738	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

New Ferrocene Formates Bearing Isoxazole Moieties: Synthesis, Characterization, X-ray Crystallography, and Preliminarily Cytotoxicity against A549, HCT116, and MCF-7 Cell Lines

Abstract Play Pause

Related Journals

Related Books

Abstract